Literature DB >> 1570171

Induction of macrophage activation and opsonizing antibodies by Trypanosoma cruzi subpopulations.

A M Celentano1, S M González Cappa.   

Abstract

Macrophage activation and production of opsonizing antibodies were studied in mice either infected with a lethal and reticulotropic Trypanosoma cruzi strain, RA, or with a non lethal and myotropic strain, CA-I, as well as with a clone, K98 (derived from CA-I), similar to the parental strain. Measurement of macrophage respiratory burst by chemiluminescence disclosed that T. cruzi infection induced an enhancement of the respiratory burst, no matter the parasite subpopulation employed. But, while in mice surviving RA infection the respiratory burst was higher than during the acute period and parasitaemia was efficiently controlled, in mice infected with K98 enhanced respiratory burst coexisted with measurable levels of parasitaemia either at acute or chronic infection periods. Macrophage activation was also proved by enhanced trypanocidal activity in macrophages derived from mice infected with any of the parasite subpopulations. Sera from RA mice opsonized and lysed T. cruzi bloodstream forms efficiently, whereas sera from CA-I or K98 mice neither lysed nor opsonized this parasite stage. All three subpopulations assayed here showed IgG bound to their membranes in vivo and similar capping kinetics, but only antibodies bound to RA parasites invariably triggered lysis. Therefore, the role played by macrophage activation in resistance and control of Pm levels is related to some features of each T. cruzi subpopulation, such as its capacity to invade macrophages and to elicit opsonizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570171     DOI: 10.1111/j.1365-3024.1992.tb00458.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

1.  Trypanosoma cruzi infection modulates in vivo expression of major histocompatibility complex class II molecules on antigen-presenting cells and T-cell stimulatory activity of dendritic cells in a strain-dependent manner.

Authors:  Catalina D Alba Soto; Gerardo A Mirkin; Maria E Solana; Stella M González Cappa
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

2.  Immunodepression induced by Trypanosoma cruzi and mouse hepatitis virus type 3 is associated with thymus apoptosis.

Authors:  L Verinaud; M A Da Cruz-Höfling; J K Sakurada; H A Rangel; J Vassallo; D Wakelin; H F Sewell; I J Camargo
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

3.  Mice infected with Trypanosoma cruzi produce antibodies against the enzymatic domain of trans-sialidase that inhibit its activity.

Authors:  M S Leguizamón; O E Campetella; S M González Cappa; A C Frasch
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  Trypanosoma cruzi induces regulatory dendritic cells in vitro.

Authors:  Carolina Verónica Poncini; Catalina Dirney Alba Soto; Estela Batalla; Maria Elisa Solana; Stella Maris González Cappa
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

5.  A lytic monoclonal antibody to Trypanosoma cruzi bloodstream trypomastigotes which recognizes an epitope expressed in tissues affected in Chagas' disease.

Authors:  N W Zwirner; E L Malchiodi; M G Chiaramonte; C A Fossati
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Nonimmune Cells Contribute to Crosstalk between Immune Cells and Inflammatory Mediators in the Innate Response to Trypanosoma cruzi Infection.

Authors:  Maria Pilar Aoki; Eugenio Antonio Carrera-Silva; Henar Cuervo; Manuel Fresno; Núria Gironès; Susana Gea
Journal:  J Parasitol Res       Date:  2011-08-18

7.  Inhibition of HIV-1 replication in human monocyte-derived macrophages by parasite Trypanosoma cruzi.

Authors:  Guadalupe Andreani; Ana M Celentano; María E Solana; Silvia I Cazorla; Emilio L Malchiodi; Liliana A Martínez Peralta; Guillermina L Dolcini
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.